Coversyl

Quick links to important sections

Coversyl

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coversyl

Property Description
Active Ingredient Perindopril
Form Tablet (Oral Solid Dosage)
Pharmacological Class Angiotensin-Converting Enzyme (ACE) Inhibitor
Common Purpose Systemic blood pressure reduction
Origin Synthetic Compound

What Type of Medicine is Coversyl (Perindopril)?

Coversyl is a prescription-only pharmaceutical preparation classified as a cardiovascular agent belonging to the Angiotensin-Converting Enzyme (ACE) Inhibitor class. This classification means the medication’s primary function is to influence the body’s long-term system for regulating blood pressure, specifically the Renin-Angiotensin-Aldosterone System (RAAS). Perindopril belongs to the C09AA group of ACE inhibitors, which are key modulators of vascular function. It is widely clinically recognized for its efficacy in establishing a foundational therapy to modulate vascular tone and fluid balance. Unlike medications that primarily affect the heart rate, the ACE Inhibitor class achieves its purpose by intervening chemically to reduce the systemic factors that contribute to high pressure.


The Composition and Purpose of the Active Ingredient

The active chemical component defining Coversyl is Perindopril, a synthetic compound manufactured as an oral solid dosage form (a tablet). Perindopril is distinguished from other agents in its class because it functions as an inactive prodrug, which the body must biochemically convert into the potent active metabolite, Perindoprilat, primarily in the liver. This mechanism is critical for its therapeutic effect. The development of Perindopril has included formulation as two primary salt forms—tert-butylamine and arginine. Perindopril is administered orally and is rapidly absorbed and hydrolyzed to its active form. The overarching purpose of this structure is to provide a consistent systemic effect that leads to the reduction of blood pressure and helps stabilize the strain placed on the heart and circulatory system, acting as a systematic tool for long-term cardiovascular stability.

Regulatory References

  1. Renin-Angiotensin-Aldosterone System (RAAS)
  2. MedlinePlus Drug Information
  3. Perindopril

What side effects are possible with Coversyl?

Possible Side Effects and Safety Information

The safety profile of Coversyl (perindopril) is officially classified by regulatory bodies based on the frequency and type of documented adverse reactions. These effects are grouped according to the physiological system involved.

Frequency-Classified Adverse Reactions

Adverse reactions that are Common (occurring in 1% to <10% of patients) include a persistent, non-productive cough, dizziness, headache, asthenia (weakness), and gastrointestinal issues such as nausea, vomiting, or diarrhea. Reactions classified as Uncommon (0.1% to <1%) include mood changes, sleep disturbances, rash, and the potential for Angioedema (swelling).

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight Angioedema (swelling of the face, throat, or tongue) as a serious, albeit rare, adverse reaction that requires immediate attention due to the risk of airway obstruction. Other serious, rare effects documented include blood disorders such as Neutropenia, and the risk of Hepatic Failure. The use of Coversyl is contraindicated in patients with a history of angioedema related to previous ACE inhibitor use.

Population and Time-Related Safety

Specific safety considerations exist for certain populations. The medication is contraindicated during the second and third trimesters of pregnancy due to documented risk of injury and death to the fetus. For older adults and patients with renal impairment, the body’s elimination of the active metabolite is reduced. Safety patterns indicate that symptomatic low blood pressure and dizziness are most likely to occur at the initiation of therapy or following a dose increase.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation identifies that the most likely clinical manifestation of an overdose with Coversyl (Perindopril) is severe hypotension, a profound drop in blood pressure. This effect is central to the overdose profile and can lead to significant physiological consequences, primarily affecting the renal system.

Documented overdose presentations and outcomes include:

  • Severe Hypotension and Bradycardia (abnormally slow heart rate).
  • Hyperkalemia (elevated serum potassium levels).
  • Oliguria and Azotemia, potentially progressing rarely to Acute Renal Failure or death in severe, unmanaged cases of excessive hypotension.

Emergency Actions Required

The regulator mandates that immediate medical attention must be sought upon any suspicion of overdose. Emergency services must be contacted immediately if the affected individual experiences collapse, a seizure, difficulty breathing, or loss of consciousness.

Management is strictly symptomatic and supportive, as no specific antidote is known for Perindopril. Treatment interventions documented in prescribing information include placement of the patient in a supine position and administering an intravenous infusion of physiological saline to restore volume and blood pressure. Hospital monitoring is required, including the measurement of electrolytes, blood pressure, and pulse. The active metabolite, Perindrilat, is known to be removable by hemodialysis.

Therapeutic Uses of Coversyl

Quick Facts

  • Aids in the management of high blood pressure (hypertension).
  • Indicated for treating the symptoms of heart failure.
  • Used in patients with stable coronary artery disease to help reduce the risk of cardiac events.

What Coversyl Treats: Main Uses and Benefits

Coversyl (perindopril) is a prescription medication used to address specific cardiovascular and circulatory conditions. The primary therapeutic domain is the management of arterial hypertension, commonly known as high blood pressure. Treatment aims to assist in maintaining blood pressure levels within a desirable range.

The medication is also indicated for the treatment of symptomatic heart failure. In this setting, it is used as part of a comprehensive therapeutic regimen to help address the condition, which is characterized by the heart's reduced ability to adequately pump blood.

Additionally, Coversyl has an approved use for individuals diagnosed with stable coronary artery disease. In these patients, the treatment is employed to help in the reduction of the risk of cardiac events, such as a heart attack. This application is indicated for patients with a history of myocardial infarction and/or revascularization.

This medication is an established option that may be used alone or in combination with other pharmaceutical agents as determined by a healthcare provider.

Eligibility and Restrictions for Use

Coversyl (perindopril) eligibility is strictly defined by regulatory authorities and is determined by patient history and physiological state. The medicine is contraindicated and must not be used by specific populations. This includes patients with a history of angioedema, whether hereditary, idiopathic, or related to prior use of any Angiotensin-Converting Enzyme (ACE) inhibitor.

Use is also prohibited for women in the second and third trimesters of pregnancy. Furthermore, eligibility is restricted based on organ function: use is typically contraindicated in cases of severe renal impairment (creatinine clearance below 30 mL/min). Patients with moderate renal impairment or hepatic impairment require careful monitoring and may need a lower starting dose.

Age-related rules establish that Coversyl is not recommended for children and adolescents under 18 years because safety and efficacy have not been formally established. Use in older adults is permitted, but requires an assessment of kidney function. Finally, the medicine is contraindicated for patients on certain extracorporeal treatments (like high-flux dialysis) and those taking aliskiren who also have diabetes or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Coversyl (perindopril) is defined by regulatory documents and centers on pharmacodynamic risks and pharmacokinetic modifications.

Contraindicated and High-Risk Combinations

  • Sacubitril/Valsartan: This combination is strictly contraindicated due to a significantly increased risk of angioedema. A mandatory 36-hour separation period is required when switching between these therapies.
  • Aliskiren: Co-administration is contraindicated in patients with diabetes mellitus or those with renal impairment (GFR less than 60 mL/min/1.73m^2).
  • High-Flux Dialysis Membranes: Concomitant treatment during extracorporeal blood procedures using certain high-flux membranes is restricted due to the documented risk of severe reactions.

Pharmacodynamic and Exposure Interactions

Coversyl's effects may be amplified by agents with similar actions:

  • Potassium-Elevating Agents: Co-administration with potassium-sparing diuretics or potassium supplements results in an additive pharmacodynamic effect, increasing the risk of hyperkalemia.
  • Lithium: Perindopril reduces the clearance of lithium, officially resulting in increased serum lithium levels and toxicity risk.
  • NSAIDs: Use alongside Non-Steroidal Anti-Inflammatory Drugs may lead to a loss of the antihypertensive effect and increased risk of renal function deterioration.
  • Food: This is a pharmacokinetic interaction; food reduces the bioavailability of the active metabolite, perindoprilat.
  • Population-Specific Note: In elderly patients and those with renal impairment, the clearance of the active metabolite is documented as being reduced, resulting in increased plasma exposure.

Mechanism of Action

How Perindopril (Coversyl) Modulates the Renin-Angiotensin System

Coversyl, which contains the prodrug perindopril, undergoes in vivo hydrolysis, primarily in the liver, to form its active metabolite, perindoprilat. This metabolite functions as a competitive inhibitor of the enzyme Angiotensin-Converting Enzyme (ACE), also known as kininase II.

Perindoprilat binds to the ACE active site, preventing the enzymatic conversion of the inactive decapeptide Angiotensin I (AT-I) into the potent vasoconstrictor, Angiotensin II (AT-II). This inhibition leads to a reduction in circulating AT-II concentration.

Decreased AT-II levels result in two primary system-level consequences: a reduction in vasoconstriction of arterial and venous smooth muscle, and a diminished stimulation of the adrenal cortex to release aldosterone. Lowered aldosterone secretion subsequently reduces the renal reabsorption of sodium and water in the distal tubules. Furthermore, ACE is responsible for the degradation of the vasodilator bradykinin. Inhibition of ACE therefore leads to an accumulation of bradykinin, which augments the effect of vasodilation. The resulting molecular and physiological modulation is a net decrease in systemic vascular resistance and circulatory volume.

Dosage and Administration Information

How Coversyl (Perindopril) is Used

Coversyl is an oral solid dosage (tablet) administered according to specific schedules outlined in prescribing information. The medication is used as a long-term therapy for chronic cardiovascular conditions and requires adherence to a defined protocol for initiation and maintenance.

Official Administration Protocol

The primary route of administration is oral, with the standard frequency being once daily. It is recommended to take the tablet before a meal in the morning to optimize the absorption of its active metabolite, perindoprilat.

Dosing Initiation and Titration

Treatment begins with a low, specified starting dose, which varies based on the condition being addressed (e.g., hypertension or heart failure). This initial dose is followed by a gradual dose adjustment, or titration, over a period of weeks until the appropriate long-term maintenance dose is reached. For instance, maintenance dose ranges are typically established between 4 mg to 8 mg daily for hypertension.

Population-Specific Adjustments

Specific dose modifications are required for certain populations. Older adults typically begin therapy with a lower initial dose, and those with renal impairment require dose adjustment based on creatinine clearance to prevent accumulation. In dialysis patients, the dose must be administered on the day of dialysis, specifically after the procedure. Use in pediatric patients (under 18 years) is not generally established or recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Coversyl (Perindopril)


Evidence Supporting Use in High Blood Pressure (Arterial Hypertension)

This section will summarize the types of Randomized Controlled Trials (RCTs) and systematic reviews that explored the available evidence for perindopril in studies of high blood pressure, focusing on the outcomes that researchers measured, such as changes in systolic and diastolic readings.

Research into perindopril's use for high blood pressure was evaluated in numerous study designs, including short-term and long-term Randomized Controlled Trials. The primary outcomes that researchers examined were the measurements of blood pressure, including both the top number (systolic) and the bottom number (diastolic), as outcomes related to systemic or functional imbalance.

Findings describe patterns observed in the studies where data show patterns related to blood pressure measurements across the observed populations. These patterns helped contextualize how the medicine was observed in studies comparing it to an inactive substance (placebo) or other medicines used for blood pressure management.


Evidence Supporting Use in Stable Coronary Artery Disease

For patients with stable coronary artery disease (a condition marked by functional limitations due to blood vessel narrowing), the evidence comes primarily from large-scale, placebo-controlled RCTs. These trials were designed to observe responses over defined time intervals. The key outcomes monitored were major vascular events, such as cardiovascular death, non-fatal heart attack, and cardiac arrest.

The main studies reported measurements that showed the rate of these major vascular events occurring in the group receiving perindopril compared to the placebo group over the study period. Findings describe patterns observed in the studies where the occurrence of heart attack and cardiovascular death was observed in some studies in the observed populations. The results apply only to the populations studied.


Evidence Supporting Use in Symptomatic Heart Failure

Perindopril was studied for symptomatic heart failure, a condition where symptoms may vary in intensity, using both individual RCTs and larger meta-analyses that pool data across multiple studies. Studies explored outcomes related to physiological strain or stress, primarily focusing on the frequency of hospitalization due to heart failure and all-cause mortality.

Evidence is limited in that perindopril was observed in heart failure as part of a multi-drug regimen, meaning it may be challenging to attribute all measured changes solely to perindopril. Additionally, data for certain groups remain insufficient regarding long-term measurements of quality of life.


Evidence Supporting Use in Preventing Recurrent Stroke

Perindopril was observed in large-scale RCTs exploring the prevention of recurrent stroke or TIA (transient ischemic attack) in individuals who have already experienced one of these conditions associated with acute or disruptive episodes. The key measurement being the occurrence of total stroke (fatal or non-fatal).

Research describes patterns observed in the studies related to the incidence of total stroke in the group studied compared to the control group over the follow-up duration of approximately four years. Data show patterns related to a difference in measured events when perindopril was studied in a combination regimen (with a diuretic) compared to when it was studied alone.


Key Evidence Gaps and Areas of Scientific Uncertainty

While a large body of evidence is available, some research limitations frame the current state of knowledge. For example, some of the most consistent findings related to stroke prevention were observed in studies where perindopril was studied in a combination regimen, meaning the impact of monotherapy alone is less clearly characterized for that outcome.

Additionally, data for certain groups remain insufficient. Evidence is limited regarding its use in children, and published research is not available for pregnant women. Comparative evidence is lacking from large-scale studies designed to directly compare the long-term, hard-to-measure outcomes of perindopril against every other similar medicine in the same class.

Frequently Asked Questions (FAQ)

Common questions about Coversyl (FAQ)


Q: Can a person stop taking Coversyl suddenly if they feel better?

A: Coversyl is described in official product information as a long-term therapy intended for chronic cardiovascular conditions. Treatment is typically initiated and then adjusted (titrated) over time to reach a maintenance dose. Discontinuation of this treatment is generally subject to review by a healthcare provider, as stopping may cause the underlying chronic condition to return or worsen.


Q: Does taking Coversyl affect cholesterol levels?

A: Regulatory documents indicate that the medicine's primary action is on blood pressure and fluid regulation, not directly on cholesterol levels (lipids). Although cholesterol levels are sometimes monitored in clinical trials, official product labeling generally does not list effects on cholesterol as a common adverse reaction or a core mechanism of action.


Q: Does alcohol consumption change how Coversyl works?

A: Official sources note that alcohol may have additive effects with Coversyl in lowering blood pressure. This combination could increase the risk of side effects such as dizziness, lightheadedness, and fainting. Given this heightened risk, official information suggests that alcohol use merits discussion with a healthcare professional.


Q: Is there evidence that Coversyl helps protect the kidneys?

A: While the drug's mechanism is related to circulatory factors that influence the kidneys, the regulatory emphasis is on the mandatory requirement to monitor renal function (kidney function) closely during therapy, especially when starting the medication or changing the dose. This is done to ensure the kidneys are functioning as expected.


Q: What happens if a dose of Coversyl is missed?

A: Regulatory documents suggest that a dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, official guidance indicates that the missed dose should be skipped, and the regular schedule continued. It is specifically advised not to take a double dose to compensate for the missed one.


Q: Can Coversyl be crushed or split?

A: Official drug information generally instructs patients to swallow the tablet whole. Manipulating tablets (such as crushing or splitting) is typically not recommended unless explicit instruction is provided by a healthcare professional. This helps ensure the correct absorption and consistent therapeutic effect of the medication.


Q: Does long-term use of Coversyl require specific monitoring tests?

A: Yes. Due to the drug's mechanism of action, official product labels specify that blood tests for renal function and serum potassium levels should be monitored closely and regularly throughout long-term treatment. For patients also taking lithium, specific monitoring of lithium levels is also required.


Q: What is the typical timeframe for a doctor to review treatment with Coversyl?

A: While there is no fixed interval for all patients, initial dose adjustment is a formal process that occurs over several weeks. Clinical guidance based on regulatory data often recommends monitoring blood pressure, renal function, and potassium at baseline, within the first few weeks, and periodically (e.g., every few months) once the stable maintenance dose is achieved.


Q: Does high salt intake reduce the effect of Coversyl?

A: Regulatory documents confirm that Coversyl works to help regulate sodium and water balance, and high salt intake may reduce the medication's intended effect. Therefore, managing salt intake is considered a factor that may support the medication’s intended systemic effect on blood pressure.


Q: What should be done if someone accidentally takes too much Coversyl?

A: Accidentally taking too much Coversyl can lead to hypotension (very low blood pressure) and other side effects. Immediate emergency medical attention is warranted. Treatment often involves placing the patient in a supine position and administering intravenous fluid replacement to restore blood pressure and volume.


Q: Does Coversyl interact with medicines used for depression or anxiety?

A: Official drug labels specifically list an interaction risk with Lithium, which is a medication used to stabilize mood. No systematic interactions are typically listed for the major classes of antidepressants (e.g., SSRIs/SNRIs); however, discussion of all combined therapies is generally recommended.


Q: Is Coversyl commonly prescribed to younger adults?

A: Official prescribing information provides dosing guidelines for the standard adult population and for older adults. Regulatory information typically does not track or comment on the commonness of prescribing patterns for younger adults, but use in children and adolescents (under 18) is generally not recommended.


Q: Does stress impact the action of Coversyl?

A: Coversyl functions by acting on the Renin-Angiotensin-Aldosterone System (RAAS), a physiological pathway known to be activated by various forms of physical and psychological stress. While the label does not explicitly detail the impact of psychological stress, the drug’s mechanism is directly linked to the body’s core systems involved in stress responses and blood pressure regulation.


Q: Is there any difference between Coversyl and Coversyl Plus?

A: Coversyl contains only the active ingredient Perindopril (an ACE inhibitor). Coversyl Plus is a combination product that contains Perindopril alongside a diuretic (often Indapamide). The combination aims to achieve a broader effect on blood pressure and fluid balance.


Q: What is the difference between Coversyl and other 'pril' blood pressure medicines?

A: All 'pril' medicines belong to the ACE inhibitor class, but they differ in chemical structure and how the body processes them. Coversyl’s active component, Perindopril, is described as a prodrug, meaning the body must convert it into its active form, perindoprilat, to work. Other ACE inhibitors may be active drugs from the start, or have different elimination pathways.


Q: How does Coversyl compare to ARBs (Angiotensin II Receptor Blockers)?

A: Coversyl (an ACE inhibitor) works by blocking the creation of Angiotensin II, a chemical that narrows blood vessels. ARBs work by blocking the receptor that Angiotensin II binds to. Both classes achieve blood pressure reduction but intervene at different points in the RAAS pathway. Direct comparative trials are often not noted in the label.


Q: Can people with diabetes safely use Coversyl?

A: Official regulatory documents caution that Coversyl requires specific monitoring in people with diabetes. It is strictly contraindicated (prohibited) for use with the medicine Aliskiren in diabetic patients due to a significantly increased risk of side effects. General use without Aliskiren is permitted but requires careful monitoring of kidney function and potassium.


Q: What is the risk of an allergic reaction to Coversyl?

A: The official product information lists Angioedema (swelling of the face, tongue, or throat) as a serious, but Uncommon (less than 1% of patients), adverse reaction. Coversyl is strictly contraindicated (prohibited) in anyone with a history of angioedema related to any ACE inhibitor.


Q: What are the signs of a serious side effect from Coversyl, like angioedema?

A: Signs of the serious side effect angioedema include swelling of the face, lips, tongue, or throat, or difficulty swallowing or breathing. Because of the risk of airway obstruction, these symptoms are highlighted in official documents as requiring immediate medical attention.


Q: Do you have to take Coversyl at the same exact time every day?

A: Official guidance recommends taking the tablet around the same time every day, typically in the morning before a meal. This helps maintain consistent levels of the medication in your body and assists with adherence to the treatment schedule.


Q: Why is it important to check blood pressure while taking Coversyl?

A: Regulatory documents underscore that checking blood pressure is essential to both ensure the drug is effective and to monitor for the risk of symptomatic hypotension (excessively low blood pressure). This issue is most likely to occur at the beginning of treatment or after a dose is increased.


Q: Is it possible to take Coversyl with other blood pressure medications?

A: Yes. Official documents confirm that Coversyl may be used alone or in combination with other classes of antihypertensive therapy, such as diuretics. However, specific combinations, such as with Aliskiren in patients with diabetes or renal impairment, are strictly contraindicated.


Q: Why is Coversyl listed as a prescription-only medicine?

A: Coversyl is designated as a prescription-only medicine because its use requires medical supervision to manage potential serious risks. These risks include symptomatic hypotension, elevated potassium levels (hyperkalemia), angioedema, and the necessity for mandatory dose adjustment based on the patient's renal (kidney) function.

How should Coversyl be stored and disposed of?

How to Store and Dispose of Coversyl (Perindopril)


Coversyl tablets must be stored according to official label specifications to maintain stability and effectiveness.

  • Temperature and Protection: Do not store the medicine above 30 C (eighty-six degrees Fahrenheit), and keep it from freezing. Store in the original package to protect the contents from moisture and direct light. The container should be kept tightly closed.
  • Child Safety: This medicine must be kept out of the sight and reach of children.
  • Disposal: Do not use the tablets after the expiry date on the packaging. Unused or expired Coversyl must not be thrown away via wastewater or mixed with household trash. Dispose of the product in accordance with local requirements by utilizing drug take-back programs or consulting a pharmacist for guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coversyl found in:

A-Z Index: